NIOSHTIC-2 Publications Search

Development of an ELISA using polypeptide fragments of hemoglobin-acrylamide adducts for biological monitoring of acrylamide exposure.

Striley CAF; Biagini RE; Snawder JE

Abstr Pap - Am Chem Soc 2003 Sep; 226(Pt 1):U88 033-ARGO

http://oasys2.confex.com/acs/226nm/techprogram/P677715.HTM

20031842

Acrylamide (AA), a probable human carcinogen and genotoxicant, is widely used in industry and agriculture. Acrylamide and its metabolite, glycidamide (GA), are known to form hemoglobin (Hb-AA) adducts that can be used as a biomarkers of exposure. Presently, a modified Edman Degradation followed by GC/MS (ED-GC/MS) analysis is used to measure Hb-AAs. Screening large populations for AA exposure with ED-GC/MS is time consuming, labor intensive and expensive. We are developing an Enzyme Linked Immunosorbant Assay (ELISA) technique to evaluate HIJ.AA with a minimum sample preparation and analysis time. Both AA and GA bind to Hb at the N-terminal valine (N-Term-Val) residue. We synthesized AA- and GA-modified-N-Term-Val decapeptides, homologous with both the alpha and beta chain of Hb. Polyclonal anti-AA- and GA-modlified. N-Term-Val decapeptide antibodies are then used in the development of a high throughput competetive direct ELISA to evaluate AA exposure in humans.

Agricultural-chemicals; Metabolites; Metabolic-activation; Biomarkers; Exposure-levels; Exposure-assessment; Blood-analysis; Industrial-hazards; Agriculture; Agricultural-industry; Cancer

Cynthia A. F. Striley, Biomonitoring and Health Assessment Branch, CDC/NIOSH, 4676 Columbia Parkway, Mailstop C-26, Cincinnati, OH 45226

ACSRAL

79-06-1

20030901

Abstract

chs3@cdc.gov

2003

0065-7727

DART

Abstracts of Papers - American Chemical Society

OH